Home About us Editorial board Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 293
  • Home
  • Print this page
  • Email this page
ARTICLE
Year : 2007  |  Volume : 14  |  Issue : 4  |  Page : 355-357

Endometrial carcinoma following treatment for breast carcinoma in a Nigerian female. A case report and review of the literature


Department of Morbid Anatomy Lagos University Teaching Hospital

Correspondence Address:
E K Abudu
Department of Morbid Anatomy Lagos University Teaching Hospital

Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

Tamoxifen is the primary hormonal therapy for breast cancer as well as its chemoprevention. It is used in the management of breast cancer because of its anti oestrogenic effect. It is however an agonist on the endometrium with undesirable effects of endometrial proliferation with the risk of endometrial hyperplasia and carcinoma. Several authors have reported cases of endometrial hyperplasia and carcinoma following tamoxifen therapy for breast carcinoma. No such report has been made from Nigeria . This paper presents the first case of endometrial carcinoma following tamoxifen therapy for breast carcinoma in a 52 year old Nigerian female. It also highlights the recommended guidelines for the follow up of women with breast cancer on tamoxifen therapy.


[PDF Not available]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed305    
    Printed6    
    Emailed0    
    PDF Downloaded0    
    Comments [Add]    

Recommend this journal